Climb Bio offers investors exposure to two key immunology assets: CLYM116 for IgA nephropathy and budoprutug. Click for more ...

Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and ...

Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, ...

For children with high-risk B-cell acute lymphoblastic leukemia (ALL), replacing part of their intensive chemotherapy with ...

Why Is CRBU Stock Falling Today? Caribou Biosciences Falls After Halting CAR-T Programs and Exploring Strategic Alternatives ...

Spread the loveImagine a future where cancer treatments are not just effective, but hyper-personalized, designed with such ...

Obexelimab has been evaluated in nine clinical trials in a total of 667 subjects, including MoonStone. Obexelimab was well tolerated and demonstrated clinical activity across these clinical trials.

Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality ...

According to the experts, clinicians should consider CAR T-cell therapy for patients with severe autoimmune disease that ...

A two-round expert elicitation among German and Austrian hematologists has produced a consensus list of prognostic factors ...

A new case report documents 127 days of persistent SARS-CoV-2 RNA positivity in a woman with chronic lymphocytic leukaemia, ...

Caribou Biosciences is discontinuing its two allogeneic CAR-T programs and exploring strategic alternatives to maximize shareholder value. Caribou Biosciences, Inc. announced that it is exploring ...